NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy
Novartis (NVS) shares fell 14% after a late-stage trial for del-desiran in myotonic dystrophy type 1 failed its primary test, marking its second trial failure in a week. The drug showed activity on secondary measures, and the company will review data. Dyne Therapeutics (DYN) and Sarepta Therapeutics (SRPT) also declined in sympathy.
How this was made
The 30-second read
Why it matters
The failure triggered a sharp sell‑off in Novartis and pressured peer companies in the same therapeutic area.
Market read
Primary biotech news with immediate price impact; relevant for traders focused on pharma/biotech equities.
What to watch
Novartis still reports activity on secondary endpoints and maintains its longer‑term outlook, which could cushion the fallout.
Background
Novartis announced a Phase 3 trial failure for del‑desiran in myotonic dystrophy type 1, marking its second miss in a week after a heart‑drug trial.
Ticker impact
Novartis (NVS) reported its Phase 3 HARBOR trial failed primary endpoint, causing a 14% drop, its worst day in 20+ years.
Expect further downside pressure; potential short‑term sell‑off.
Large‑cap biotech trial miss with double‑digit move; market reaction already strong.
Dyne Therapeutics (DYN) shares fell 16% as investors reacted to Novartis' trial miss in the same disease area.
Likely continued weakness pending own data release.
Peer failure creates sector pressure; no new data from DYN itself.
Sarepta Therapeutics (SRPT) dropped 7% following the same Novartis trial failure, affecting its DM1 pipeline perception.
Potential further decline until company clarifies its own pipeline.
Peer disappointment influences investor sentiment; no direct news from SRPT.
Market effects
DM1 and rare‑disease biotech sector faces heightened risk perception.
European and US biotech indices may see modest pullback.
Limited to biotech niche; broader market largely unaffected.
Counterpoint
Some investors may view the sell‑off as an overreaction and look for a buying opportunity on the dip.
Key entities
- CompanyNovartis
Swiss pharma giant, ticker NVS.
- CompanyDyne Therapeutics
Biotech developing zbasivarsen for DM1, ticker DYN.
- CompanySarepta Therapeutics
Biotech with SRP‑1003 program for DM1, ticker SRPT.
